Amneal Pharmaceuticals (AMRX) Financials

$7.50 +0.15 (+2.04%)

As of 05/15/2025 04:00 PM Eastern

Annual Income Statements for Amneal Pharmaceuticals

This table shows Amneal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	-117	-84	-130	11	91	-362	-21	0.00	0.00
Consolidated Net Income / (Loss)	-74	-49	-255	20	69	-604	-201	169	209
Net Income / (Loss) Continuing Operations	-74	-49	-255	20	69	-604	-201	169	209
Total Pre-Tax Income	-55	-40	-248	31	-36	-220	-203	171	215
Total Operating Income	249	204	-95	153	91	-249	-20	245	285
Total Gross Profit	1,020	821	785	769	628	353	716	526	597
Total Revenue	2,794	2,394	2,212	2,094	1,993	1,626	1,663	1,034	1,018
Operating Revenue	2,794	2,394	2,212	2,094	1,993	1,626	1,663	1,034	1,018
Total Cost of Revenue	1,774	1,573	1,428	1,325	1,364	1,273	947	507	421
Operating Cost of Revenue	1,774	1,573	1,428	1,325	1,364	1,273	947	507	421
Total Operating Expenses	771	616	880	616	537	602	736	281	313
Selling, General & Admin Expense	476	430	400	366	327	290	228	109	119
Research & Development Expense	197	168	200	202	180	188	194	171	179
Other Operating Expenses / (Income)	0.00	-1.14	-5.87	7.72	11	14	16	21	-
Impairment Charge	0.00	31	13	0.71	2.68	47	39	0.00	0.00
Restructuring Charge	2.36	1.75	2.13	15	11	51	278	9.40	0.07
Other Special Charges / (Income)	96	-13	271	25	5.86	12	-20	-29	15
Total Other Income / (Expense), net	-304	-245	-153	-121	-127	28	-183	-74	-70
Interest Expense	0.00	41	0.29	0.00	0.00	-	20	2.53	0.00
Interest & Investment Income	-259	-211	-158	-136	-146	-168	-144	-71	-55
Other Income / (Expense), net	-46	6.79	5.47	15	19	197	-20	-0.19	-15
Income Tax Expense	19	8.45	6.66	11	-104	383	-1.42	2.00	5.40
Preferred Stock Dividends Declared	0.00	0.00	0.44	0.00	0.00	-	1.18	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	43	35	-125	9.55	-22	-242	-33	1.68	2.05
Basic Earnings per Share	($0.38)	($0.48)	($0.86)	$0.07	$0.62	($2.74)	($0.16)	-	$0.00
Weighted Average Basic Shares Outstanding	308.98M	176.14M	150.94M	148.92M	147.44M	132.11M	127.25M	-	0.00
Diluted Earnings per Share	($0.38)	($0.48)	($0.86)	$0.07	$0.61	($2.74)	($0.16)	-	$0.00
Weighted Average Diluted Shares Outstanding	308.98M	176.14M	150.94M	151.82M	148.91M	132.11M	127.25M	-	0.00
Weighted Average Basic & Diluted Shares Outstanding	309.97M	307.01M	303.62M	301.54M	299.82M	132.11M	127.25M	-	0.00

This table shows Amneal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	12	-31	-0.16	5.99	-92	-99	9.68	12	-6.94	-4.33	-2.69
Consolidated Net Income / (Loss)	25	-21	12	17	-82	-93	25	30	-10	-5.86	-2.39
Net Income / (Loss) Continuing Operations	25	-21	12	17	-82	-93	25	30	-10	-5.86	-2.39
Total Pre-Tax Income	37	-15	15	20	-76	-83	23	30	-9.43	-7.66	2.18
Total Operating Income	100	76	89	95	-11	14	76	80	34	36	44
Total Gross Profit	256	263	270	250	238	190	233	220	178	215	194
Total Revenue	695	731	702	702	659	617	620	599	558	610	546
Operating Revenue	695	731	702	702	659	617	620	599	558	610	546
Total Cost of Revenue	440	468	433	452	421	427	388	379	379	394	351
Operating Cost of Revenue	440	468	433	452	421	427	388	379	379	394	351
Total Operating Expenses	156	187	181	154	249	176	157	140	144	179	150
Selling, General & Admin Expense	118	129	119	116	113	109	113	106	102	102	100
Research & Development Expense	42	60	61	36	39	50	41	38	39	46	50
Other Operating Expenses / (Income)	-5.12	-3.99	1.97	1.04	0.98	-3.35	0.96	0.83	0.42	-6.37	0.09
Restructuring Charge	0.57	0.49	0.17	0.22	1.47	0.11	1.04	0.08	0.51	0.10	0.62
Other Special Charges / (Income)	0.00	1.78	-1.18	0.70	94	-11	0.50	-4.35	2.02	24	-1.14
Total Other Income / (Expense), net	-63	-91	-73	-75	-65	-98	-53	-50	-44	-44	-42
Interest & Investment Income	-57	-62	-66	-66	-66	-60	-51	-51	-49	-47	-42
Other Income / (Expense), net	-5.92	-29	-7.88	-9.35	0.93	2.70	-1.78	0.43	5.44	3.63	0.22
Income Tax Expense	13	5.42	3.67	3.62	6.16	9.86	-2.08	0.00	0.67	-1.80	4.57
Net Income / (Loss) Attributable to Noncontrolling Interest	12	10	12	11	9.97	5.31	15	18	-3.15	-1.53	0.30
Basic Earnings per Share	$0.04	($0.10)	$0.00	$0.02	($0.30)	($0.57)	$0.06	$0.08	($0.05)	($0.03)	($0.02)
Weighted Average Basic Shares Outstanding	311.05M	308.98M	309.65M	309.12M	307.28M	176.14M	154.22M	153.74M	152.11M	150.94M	151.39M
Diluted Earnings per Share	$0.04	($0.10)	$0.00	$0.02	($0.30)	($0.57)	$0.06	$0.08	($0.05)	($0.03)	($0.02)
Weighted Average Diluted Shares Outstanding	323.96M	308.98M	309.65M	318.96M	307.28M	176.14M	159.69M	154.89M	152.11M	150.94M	151.39M
Weighted Average Basic & Diluted Shares Outstanding	313.42M	309.97M	309.84M	309.54M	308.65M	307.01M	306.54M	306.31M	305.45M	303.62M	303.59M

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	19	64	-222	-90	194	-66	141	41	-29
Net Cash From Operating Activities	295	346	65	242	379	1.71	250	234	115
Net Cash From Continuing Operating Activities	295	346	65	242	379	1.71	250	234	115
Net Income / (Loss) Continuing Operations	-74	-49	-255	20	69	-604	-201	169	209
Consolidated Net Income / (Loss)	-74	-49	-255	20	69	-604	-201	169	209
Depreciation Expense	236	229	240	233	235	207	137	46	33
Amortization Expense	29	12	8.60	9.20	8.68	43	16	4.59	3.00
Non-Cash Adjustments To Reconcile Net Income	163	225	133	115	129	109	294	23	26
Changes in Operating Assets and Liabilities, net	-59	-72	-62	-136	-63	246	3.78	-8.51	-156
Net Cash From Investing Activities	-63	-69	-174	-194	-318	-20	-396	-99	-125
Net Cash From Continuing Investing Activities	-63	-69	-174	-194	-318	-20	-396	-99	-125
Purchase of Property, Plant & Equipment	-60	-47	-49	-51	-62	-47	-83	-95	-123
Acquisitions	-15	-22	-127	-148	-256	-50	-339	-20	-1.85
Divestitures	12	0.00	0.00	-	-	35	0.00	16	0.00
Other Investing Activities, net	0.00	0.00	1.00	5.00	0.00	43	0.00	0.00	-
Net Cash From Financing Activities	-212	-213	-107	-138	132	-46	288	-95	-19
Net Cash From Continuing Financing Activities	-212	-213	-107	-138	132	-46	288	-95	-19
Repayment of Debt	-233	-576	-125	-79	-40	-27	-839	-19	-43
Repurchase of Common Equity	0.00	0.00	-1.72	0.00	0.00	-	-12	0.00	-0.01
Payment of Dividends	-20	-71	-18	-57	-3.24	-	-183	-376	-202
Issuance of Debt	48	437	85	0.00	180	0.00	1,325	300	225
Other Financing Activities, net	-6.80	-1.93	-47	-1.90	-4.92	-19	-3.76	0.04	-0.26
Effect of Exchange Rate Changes	-1.00	0.07	-5.68	0.10	1.04	-2.25	-0.67	-	-
Cash Interest Paid	264	193	143	122	130	159	132	65	51
Cash Income Taxes Paid	15	2.50	13	-16	100	10	35	-5.78	4.92

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-50	40	29	-2.00	-47	3.50	-19	-36	116	-61	-2.29
Net Cash From Operating Activities	7.41	118	142	40	-4.41	136	81	-11	140	-23	94
Net Cash From Continuing Operating Activities	7.41	118	142	40	-4.41	136	81	-11	140	-23	94
Net Income / (Loss) Continuing Operations	25	-21	12	17	-82	-93	25	30	-10	-5.86	-2.39
Consolidated Net Income / (Loss)	25	-21	12	17	-82	-93	25	30	-10	-5.86	-2.39
Depreciation Expense	60	66	59	56	56	57	57	57	58	61	62
Amortization Expense	6.81	26	1.44	0.93	0.29	4.66	2.36	2.47	2.06	2.11	2.10
Non-Cash Adjustments To Reconcile Net Income	21	59	39	27	39	133	30	27	35	52	23
Changes in Operating Assets and Liabilities, net	-105	-12	31	-61	-17	34	-33	-128	55	-133	9.27
Net Cash From Investing Activities	-18	-16	-21	-6.47	-20	-32	-13	-12	-12	-11	-49
Net Cash From Continuing Investing Activities	-18	-16	-21	-6.47	-20	-32	-13	-12	-12	-11	-49
Purchase of Property, Plant & Equipment	-14	-22	-17	-11	-10	-12	-12	-11	-11	-11	-18
Acquisitions	-4.20	-0.60	-3.60	-0.75	-9.70	-20	-1.00	-1.15	-0.34	-	-32
Sale of Property, Plant & Equipment	0.52	-	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-39	-61	-92	-35	-23	-101	-87	-12	-13	-22	-46
Net Cash From Continuing Financing Activities	-39	-61	-92	-35	-23	-101	-87	-12	-13	-22	-46
Repayment of Debt	-236	-56	-87	-27	-63	-424	-64	-15	-73	-18	-43
Payment of Dividends	-0.07	-5.36	-5.56	-8.29	-0.59	-3.01	-32	-17	-18	-4.43	-3.21
Issuance of Debt	218	-	-	-	48	327	10	20	80	-	-
Other Financing Activities, net	-22	-0.24	0.42	0.20	-7.18	-0.11	0.22	-0.01	-2.02	-0.09	-0.27
Effect of Exchange Rate Changes	-0.47	-0.74	0.01	-0.10	-0.17	0.20	-0.30	-0.60	0.77	-3.74	-0.40
Cash Interest Paid	56	61	66	72	65	56	48	48	41	51	35
Cash Income Taxes Paid	3.61	6.16	-1.15	15	-4.57	2.07	-3.49	0.50	3.42	23	-3.20

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	3,501	3,473	3,799	3,940	4,006	3,666	4,353	1,342
Total Current Assets	1,588	1,378	1,412	1,520	1,552	1,210	1,287	772
Cash & Equivalents	111	92	26	248	341	151	213	74
Restricted Cash	7.87	7.57	9.25	8.95	5.74	1.63	5.39	3.76
Accounts Receivable	776	615	742	664	640	606	482	368
Inventories, net	612	581	531	489	491	381	457	284
Prepaid Expenses	81	83	104	110	73	70	128	42
Plant, Property, & Equipment, net	425	448	470	514	478	478	544	487
Total Noncurrent Assets	1,489	1,647	1,918	1,905	1,977	2,109	2,522	83
Noncurrent Note & Lease Receivables	56	59	63	64	68	123	0.00	-
Goodwill	597	599	599	593	523	420	426	26
Intangible Assets	732	890	1,096	1,167	1,305	1,383	1,655	45
Other Noncurrent Operating Assets	102	99	159	81	81	184	68	11
Total Liabilities & Shareholders' Equity	3,501	3,473	3,799	3,940	4,006	3,666	4,353	1,342
Total Liabilities	3,546	3,411	3,590	3,556	3,649	3,319	3,456	1,717
Total Current Liabilities	1,130	847	753	677	677	550	554	297
Short-Term Debt	324	213	90	31	45	21	22	89
Accounts Payable	758	542	541	573	619	513	532	207
Other Current Liabilities	48	91	122	76	16	18	0.00	-
Total Noncurrent Liabilities	2,416	2,565	2,838	2,879	2,972	2,769	2,903	1,421
Long-Term Debt	2,162	2,427	2,592	2,718	2,772	2,609	2,631	1,355
Capital Lease Obligations	57	59	61	60	-	61	39	40
Asset Retirement Reserve & Litigation Obligation	85	0.32	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	112	78	185	100	201	98	39	7.79
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	65	41	25	17	12	0.00	-	-
Total Equity & Noncontrolling Interests	-110	20	184	367	345	347	896	-376
Total Preferred & Common Equity	-109	20	298	360	303	232	505	-386
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Common Equity	-109	20	298	360	303	232	505	-386
Common Stock	563	542	695	661	631	610	533	11
Retained Earnings	-607	-490	-406	-276	-287	-378	-21	-383
Accumulated Other Comprehensive Income / (Loss)	-66	-32	9.94	-25	-41	-0.07	-7.76	-14
Noncontrolling Interest	-0.25	0.23	-114	6.63	42	115	392	10

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	3,365	3,461	3,510	3,456	3,687	3,701	3,627	3,874
Total Current Assets	1,510	1,513	1,485	1,380	1,456	1,422	1,307	1,420
Cash & Equivalents	59	74	44	47	87	109	145	87
Accounts Receivable	755	757	779	670	693	675	546	630
Inventories, net	601	596	576	571	576	551	529	544
Prepaid Expenses	89	82	82	87	91	82	81	150
Plant, Property, & Equipment, net	427	431	425	440	452	459	463	470
Total Noncurrent Assets	1,428	1,517	1,599	1,637	1,779	1,820	1,857	1,984
Noncurrent Note & Lease Receivables	56	58	58	60	61	62	62	64
Goodwill	597	598	599	599	599	599	599	600
Intangible Assets	689	780	820	859	983	1,015	1,055	1,159
Other Noncurrent Operating Assets	85	81	122	119	137	144	140	161
Total Liabilities & Shareholders' Equity	3,365	3,461	3,510	3,456	3,687	3,701	3,627	3,874
Total Liabilities	3,425	3,495	3,514	3,473	3,496	3,518	3,464	3,657
Total Current Liabilities	1,076	1,095	1,114	834	761	777	704	818
Short-Term Debt	322	365	436	213	107	150	130	90
Accounts Payable	695	684	632	576	561	534	482	535
Other Current Liabilities	59	47	44	43	90	90	92	193
Total Noncurrent Liabilities	2,349	2,399	2,400	2,639	2,735	2,741	2,761	2,839
Long-Term Debt	2,154	2,170	2,178	2,378	2,542	2,549	2,602	2,646
Asset Retirement Reserve & Litigation Obligation	73	85	85	85	-	-	-	-
Other Noncurrent Operating Liabilities	122	144	137	175	193	191	99	132
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	73	60	53	47	37	32	28	22
Total Equity & Noncontrolling Interests	-132	-94	-57	-64	154	151	135	194
Total Preferred & Common Equity	-132	-93	-57	-64	331	318	294	297
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-132	-93	-57	-64	331	318	294	297
Common Stock	549	556	549	542	719	711	704	687
Retained Earnings	-595	-576	-576	-582	-392	-401	-413	-402
Accumulated Other Comprehensive Income / (Loss)	-86	-74	-30	-24	3.87	8.08	3.76	13
Noncontrolling Interest	-0.33	-0.14	-0.02	0.10	-177	-167	-160	-103

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	16.73%	8.20%	5.67%	5.08%	22.51%	-2.20%	60.88%	1.52%	0.00%
EBITDA Growth	3.71%	183.79%	-61.17%	15.81%	78.87%	73.44%	-61.35%	-3.49%	0.00%
EBIT Growth	-3.59%	336.05%	-153.35%	52.14%	311.81%	-31.79%	-116.12%	-9.33%	0.00%
NOPAT Growth	22.00%	315.29%	-167.66%	53.91%	136.66%	-1,164.08%	-105.68%	-12.78%	0.00%
Net Income Growth	-51.63%	80.88%	-1,363.21%	-70.59%	111.36%	-199.83%	-218.89%	-19.15%	0.00%
EPS Growth	20.83%	44.19%	-1,328.57%	-88.52%	122.26%	-1,612.50%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-14.61%	430.84%	-73.08%	-36.20%	22,128.80%	-99.32%	6.85%	103.53%	0.00%
Free Cash Flow Firm Growth	14.52%	905.93%	-289.36%	-104.96%	41.84%	107.72%	-190.59%	0.00%	0.00%
Invested Capital Growth	-10.57%	-8.75%	-0.58%	3.93%	-6.37%	-10.52%	222.00%	0.00%	0.00%
Revenue Q/Q Growth	4.24%	0.30%	3.41%	1.30%	6.00%	-5.80%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	15.75%	-5.11%	15.75%	-2.38%	17.79%	-20.15%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	16.91%	-9.73%	19.76%	-6.38%	75.29%	-815.98%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	32.81%	-41.99%	20.75%	-23.87%	90.53%	-22.95%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	49.57%	-225.69%	5.42%	-40.09%	544.71%	22.68%	0.00%	0.00%	0.00%
EPS Q/Q Growth	55.29%	-900.00%	1.15%	-12.50%	41.86%	-5.79%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-5.67%	85.33%	-57.07%	-15.01%	70.60%	-99.45%	348.09%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-0.08%	-4.74%	68.89%	-105.15%	578.35%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-1.75%	-3.12%	-0.07%	3.16%	-4.67%	4.89%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	36.52%	34.28%	35.47%	36.73%	31.54%	21.70%	43.08%	50.90%	58.68%
EBITDA Margin	16.78%	18.89%	7.20%	19.60%	17.78%	12.18%	6.87%	28.58%	30.06%
Operating Margin	8.92%	8.54%	-4.29%	7.29%	4.57%	-15.29%	-1.18%	23.71%	27.98%
EBIT Margin	7.29%	8.82%	-4.04%	8.01%	5.53%	-3.20%	-2.37%	23.69%	26.53%
Profit (Net Income) Margin	-2.64%	-2.04%	-11.52%	0.96%	3.44%	-37.11%	-12.10%	16.38%	20.57%
Tax Burden Percent	134.29%	120.99%	102.68%	64.31%	-191.67%	274.05%	99.30%	98.83%	97.49%
Interest Burden Percent	-27.02%	-19.07%	277.36%	18.70%	-32.46%	423.24%	513.43%	69.95%	79.53%
Effective Tax Rate	0.00%	0.00%	0.00%	35.69%	0.00%	0.00%	0.00%	1.17%	2.51%
Return on Invested Capital (ROIC)	6.92%	5.13%	-2.27%	3.41%	2.19%	-5.45%	-0.62%	46.31%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.96%	-2.10%	-9.44%	0.30%	2.37%	-22.16%	-10.25%	36.05%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-888.18%	-41.19%	-83.69%	2.03%	17.31%	-91.65%	-76.68%	-136.47%	0.00%
Return on Equity (ROE)	-881.26%	-36.06%	-85.96%	5.45%	19.50%	-97.10%	-77.31%	-90.17%	0.00%
Cash Return on Invested Capital (CROIC)	18.09%	14.28%	-1.69%	-0.44%	8.76%	5.65%	-105.84%	-153.69%	0.00%
Operating Return on Assets (OROA)	5.84%	5.81%	-2.31%	4.22%	2.87%	-1.30%	-1.39%	18.25%	0.00%
Return on Assets (ROA)	-2.12%	-1.34%	-6.58%	0.51%	1.79%	-15.05%	-7.07%	12.62%	0.00%
Return on Common Equity (ROCE)	4,703.59%	-42.46%	-95.52%	4.88%	14.83%	-57.55%	-17.67%	-92.61%	0.00%
Return on Equity Simple (ROE_SIMPLE)	67.61%	-246.31%	-85.38%	5.60%	22.61%	-260.15%	-39.88%	-43.90%	0.00%
Net Operating Profit after Tax (NOPAT)	175	143	-66	98	64	-174	-14	242	278
NOPAT Margin	6.25%	5.98%	-3.00%	4.69%	3.20%	-10.70%	-0.83%	23.44%	27.28%
Net Nonoperating Expense Percent (NNEP)	9.89%	7.23%	7.17%	3.11%	-0.19%	16.71%	9.63%	10.26%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	7.17%	5.26%	-2.27%	-	-	-	-	-	-
Cost of Revenue to Revenue	63.48%	65.72%	64.53%	63.27%	68.46%	78.30%	56.92%	49.10%	41.32%
SG&A Expenses to Revenue	17.05%	17.95%	18.07%	17.46%	16.40%	17.81%	13.70%	10.55%	11.66%
R&D to Revenue	7.04%	7.01%	9.04%	9.64%	9.03%	11.56%	11.68%	16.58%	17.58%
Operating Expenses to Revenue	27.60%	25.74%	39.76%	29.43%	26.96%	37.00%	44.26%	27.19%	30.70%
Earnings before Interest and Taxes (EBIT)	204	211	-89	168	110	-52	-39	245	270
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	469	452	159	410	354	198	114	295	306
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	94.07	2.02	4.01	4.52	6.21	8.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.88	0.78	0.27	0.69	0.69	0.89	2.43	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	135.93	15.04	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.74%	6.65%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.08	1.69	1.10	1.37	1.38	1.36	2.05	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.77	1.88	1.46	1.92	1.95	2.52	4.15	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	10.54	9.96	20.23	9.80	10.99	20.68	60.45	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	24.28	21.32	0.00	23.97	35.32	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	28.32	31.47	0.00	40.93	61.01	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	16.75	13.03	49.50	16.62	10.27	2,402.12	27.59	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	10.84	11.31	0.00	0.00	15.22	22.71	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	-57.09	44.03	13.13	7.32	7.90	7.76	3.00	-3.95	0.00
Long-Term Debt to Equity	-49.82	40.55	12.70	7.24	7.77	7.70	2.98	-3.71	0.00
Financial Leverage	299.68	19.64	8.87	6.77	7.30	4.14	7.48	-3.79	0.00
Leverage Ratio	415.96	26.91	13.05	10.73	10.91	6.45	10.93	-3.57	0.00
Compound Leverage Factor	-112.40	-5.13	36.21	2.01	-3.54	27.30	56.14	-2.50	0.00
Debt to Total Capital	101.78%	97.78%	92.92%	87.98%	88.76%	88.59%	75.02%	133.86%	0.00%
Short-Term Debt to Total Capital	12.98%	7.72%	3.05%	0.96%	1.43%	0.71%	0.61%	8.07%	0.00%
Long-Term Debt to Total Capital	88.81%	90.06%	89.87%	87.02%	87.33%	87.88%	74.41%	125.79%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.59%	1.50%	-3.03%	0.74%	1.68%	3.78%	10.92%	0.92%	0.00%
Common Equity to Total Capital	-4.37%	0.72%	10.11%	11.29%	9.56%	7.64%	14.07%	-34.78%	0.00%
Debt to EBITDA	5.42	5.97	17.22	6.85	7.95	13.59	23.57	5.03	0.00
Net Debt to EBITDA	5.17	5.75	17.00	6.22	6.97	12.82	21.65	4.76	0.00
Long-Term Debt to EBITDA	4.73	5.50	16.65	6.77	7.82	13.48	23.38	4.72	0.00
Debt to NOPAT	14.57	18.87	-41.28	28.60	44.15	-15.46	-195.44	6.13	0.00
Net Debt to NOPAT	13.89	18.17	-40.74	25.99	38.71	-14.59	-179.55	5.81	0.00
Long-Term Debt to NOPAT	12.71	17.38	-39.92	28.29	43.44	-15.34	-193.86	5.76	0.00
Altman Z-Score	1.32	1.20	0.66	1.07	0.98	0.73	1.25	0.00	0.00
Noncontrolling Interest Sharing Ratio	633.73%	-17.75%	-11.13%	10.40%	23.91%	40.73%	77.15%	-2.70%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	1.41	1.63	1.88	2.24	2.29	2.20	2.32	2.60	0.00
Quick Ratio	0.78	0.83	1.02	1.35	1.45	1.38	1.26	1.49	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	456	398	-49	-13	256	180	-2,336	-804	0.00
Operating Cash Flow to CapEx	489.06%	738.40%	133.42%	474.72%	612.91%	3.61%	433.34%	247.11%	93.73%
Free Cash Flow to Firm to Interest Expense	0.00	9.76	-169.76	0.00	0.00	0.00	-118.80	-317.55	0.00
Operating Cash Flow to Interest Expense	0.00	8.47	223.71	0.00	0.00	0.00	12.72	92.49	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	7.32	56.03	0.00	0.00	0.00	9.79	55.06	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.80	0.66	0.57	0.53	0.52	0.41	0.58	0.77	0.00
Accounts Receivable Turnover	4.02	3.53	3.15	3.21	3.20	2.99	3.91	2.81	0.00
Inventory Turnover	2.97	2.83	2.80	2.70	3.13	3.04	2.55	1.79	0.00
Fixed Asset Turnover	6.40	5.22	4.50	4.22	4.17	3.18	3.23	2.12	0.00
Accounts Payable Turnover	2.73	2.91	2.56	2.22	2.41	2.44	2.56	2.45	0.00
Days Sales Outstanding (DSO)	90.85	103.46	115.99	113.67	114.17	122.14	93.27	129.80	0.00
Days Inventory Outstanding (DIO)	122.85	129.03	130.41	135.02	116.62	120.14	142.91	204.29	0.00
Days Payable Outstanding (DPO)	133.75	125.61	142.40	164.31	151.56	149.85	142.58	149.17	0.00
Cash Conversion Cycle (CCC)	79.96	106.88	104.00	84.38	79.23	92.43	93.60	184.92	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	2,380	2,661	2,916	2,933	2,823	3,015	3,369	1,046	0.00
Invested Capital Turnover	1.11	0.86	0.76	0.73	0.68	0.51	0.75	1.98	0.00
Increase / (Decrease) in Invested Capital	-281	-255	-17	111	-192	-354	2,323	1,046	0.00
Enterprise Value (EV)	4,943	4,502	3,222	4,020	3,893	4,096	6,904	0.00	0.00
Market Capitalization	2,454	1,861	604	1,444	1,370	1,442	4,040	0.00	0.00
Book Value per Share	($0.35)	$0.06	$0.98	$1.20	$1.01	$0.78	$1.69	$0.00	$0.00
Tangible Book Value per Share	($4.64)	($4.79)	($4.60)	($4.64)	($5.08)	($5.25)	($5.28)	$0.00	$0.00
Total Capital	2,498	2,760	2,952	3,193	3,174	3,039	3,588	1,109	0.00
Total Debt	2,543	2,699	2,743	2,809	2,817	2,692	2,691	1,485	0.00
Total Long-Term Debt	2,219	2,486	2,653	2,778	2,772	2,671	2,670	1,395	0.00
Net Debt	2,424	2,600	2,707	2,552	2,470	2,539	2,473	1,407	0.00
Capital Expenditures (CapEx)	60	47	49	51	62	47	58	95	123
Debt-free, Cash-free Net Working Capital (DFCFNWC)	664	645	714	617	573	528	536	487	0.00
Debt-free Net Working Capital (DFNWC)	782	744	749	873	920	681	755	565	0.00
Net Working Capital (NWC)	458	531	659	843	875	660	733	475	0.00
Net Nonoperating Expense (NNE)	248	192	188	78	-4.77	429	188	73	68
Net Nonoperating Obligations (NNO)	2,424	2,600	2,707	2,550	2,466	2,668	2,473	1,422	0.00
Total Depreciation and Amortization (D&A)	265	241	249	243	244	250	154	51	36
Debt-free, Cash-free Net Working Capital to Revenue	23.76%	26.96%	32.26%	29.46%	28.74%	32.49%	32.21%	47.08%	0.00%
Debt-free Net Working Capital to Revenue	28.00%	31.10%	33.86%	41.72%	46.17%	41.89%	45.37%	54.62%	0.00%
Net Working Capital to Revenue	16.39%	22.20%	29.79%	40.26%	43.90%	40.57%	44.06%	45.96%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.38)	($0.48)	($0.86)	$0.07	$0.62	($2.74)	($0.16)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	308.98M	176.14M	150.94M	148.92M	147.44M	299.23M	298.69M	0.00	0.00
Adjusted Diluted Earnings per Share	($0.38)	($0.48)	($0.86)	$0.07	$0.61	($2.74)	($0.16)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	308.98M	176.14M	150.94M	151.82M	148.91M	299.23M	298.69M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($2.74)	($0.16)	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	309.97M	307.01M	303.62M	301.54M	299.82M	132.11M	127.25M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	243	157	134	125	78	-97	195	223	292
Normalized NOPAT Margin	8.70%	6.56%	6.04%	5.96%	3.90%	-5.98%	11.71%	21.53%	28.69%
Pre Tax Income Margin	-1.97%	-1.68%	-11.22%	1.50%	-1.80%	-13.54%	-12.19%	16.57%	21.10%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	5.18	-307.42	0.00	0.00	0.00	-2.01	96.73	0.00
NOPAT to Interest Expense	0.00	3.51	-228.35	0.00	0.00	0.00	-0.70	95.67	0.00
EBIT Less CapEx to Interest Expense	0.00	4.03	-475.10	0.00	0.00	0.00	-4.94	59.30	0.00
NOPAT Less CapEx to Interest Expense	0.00	2.36	-396.03	0.00	0.00	0.00	-3.64	58.24	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-26.81%	-145.48%	-6.89%	283.25%	4.72%	0.00%	-90.73%	222.13%	96.26%
Augmented Payout Ratio	-26.81%	-145.48%	-7.57%	283.25%	4.72%	0.00%	-96.58%	222.13%	96.26%

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.50%	18.40%	13.29%	17.15%	18.23%	1.18%	13.65%	7.10%	12.04%	13.57%	3.21%
EBITDA Growth	207.35%	76.98%	5.92%	1.81%	-54.05%	-23.67%	23.23%	203.60%	19.99%	26.71%	14.05%
EBIT Growth	1,061.66%	174.35%	9.57%	6.96%	-124.62%	-57.41%	65.73%	140.85%	70.36%	124.88%	37.75%
NOPAT Growth	976.08%	434.02%	-17.93%	-1.93%	-131.19%	-60.61%	269.64%	157.60%	47.82%	222.43%	-343.61%
Net Income Growth	130.14%	77.78%	-53.03%	-43.45%	-709.17%	-1,493.44%	1,147.41%	112.36%	-56.25%	71.37%	60.77%
EPS Growth	113.33%	82.46%	-100.00%	-75.00%	-500.00%	-1,800.00%	400.00%	110.00%	-400.00%	25.00%	33.33%
Operating Cash Flow Growth	267.98%	-13.06%	74.20%	449.55%	-103.16%	683.13%	-13.02%	90.96%	16.09%	-136.82%	13.61%
Free Cash Flow Firm Growth	-10.99%	26.21%	54.67%	20.41%	17.47%	526.92%	305.42%	249.85%	183.97%	141.01%	-189.99%
Invested Capital Growth	-6.92%	-10.57%	-11.83%	-7.51%	-9.91%	-8.75%	-5.87%	-5.40%	-6.85%	-0.58%	2.64%
Revenue Q/Q Growth	-4.80%	3.99%	0.10%	6.46%	6.84%	-0.49%	3.50%	7.44%	-8.56%	11.77%	-2.47%
EBITDA Q/Q Growth	16.19%	-1.72%	-0.91%	210.08%	-38.77%	-41.18%	-4.75%	39.96%	-2.65%	-5.04%	180.08%
EBIT Q/Q Growth	103.75%	-42.74%	-6.03%	977.12%	-158.13%	-77.13%	-8.26%	101.85%	0.57%	-11.01%	122.61%
NOPAT Q/Q Growth	24.21%	-21.63%	-13.81%	1,144.14%	-175.71%	-87.96%	3.00%	232.10%	-4.39%	151.87%	65.03%
Net Income Q/Q Growth	218.69%	-276.42%	-29.96%	120.55%	12.50%	-472.88%	-15.67%	394.07%	-72.31%	-145.10%	99.00%
EPS Q/Q Growth	140.00%	0.00%	-100.00%	106.67%	47.37%	-1,050.00%	-25.00%	260.00%	-66.67%	-50.00%	97.50%
Operating Cash Flow Q/Q Growth	-93.73%	-16.71%	257.50%	999.25%	-103.25%	66.89%	817.38%	-108.12%	699.83%	-124.89%	174.55%
Free Cash Flow Firm Q/Q Growth	-28.06%	-14.81%	36.92%	6.07%	-25.36%	4.40%	6.59%	3.49%	444.40%	134.21%	22.25%
Invested Capital Q/Q Growth	-1.23%	-1.75%	-5.48%	1.48%	-1.51%	-3.12%	-0.86%	-1.15%	-3.88%	-0.07%	-0.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	36.80%	35.98%	38.37%	35.62%	36.11%	30.77%	37.50%	36.73%	31.96%	35.32%	35.60%
EBITDA Margin	23.21%	19.02%	20.12%	20.32%	6.98%	12.72%	21.52%	23.39%	17.95%	16.86%	19.85%
Operating Margin	14.43%	10.38%	12.64%	13.60%	-1.63%	2.30%	12.20%	13.37%	6.18%	5.91%	8.13%
EBIT Margin	13.58%	6.34%	11.52%	12.27%	-1.49%	2.74%	11.91%	13.44%	7.15%	6.50%	8.17%
Profit (Net Income) Margin	3.54%	-2.84%	1.67%	2.39%	-12.39%	-15.13%	4.04%	4.96%	-1.81%	-0.96%	-0.44%
Tax Burden Percent	65.67%	135.40%	76.23%	82.27%	108.15%	111.84%	109.04%	100.08%	107.09%	76.53%	-109.63%
Interest Burden Percent	39.70%	-33.06%	19.06%	23.69%	769.14%	-494.09%	31.08%	36.84%	-23.63%	-19.30%	4.89%
Effective Tax Rate	34.33%	0.00%	23.77%	17.73%	0.00%	0.00%	-9.04%	0.00%	0.00%	0.00%	209.63%
Return on Invested Capital (ROIC)	11.00%	8.05%	9.99%	10.90%	-1.07%	1.38%	11.21%	10.84%	3.38%	3.13%	-6.62%
ROIC Less NNEP Spread (ROIC-NNEP)	9.33%	5.11%	7.76%	8.51%	-3.93%	-2.51%	9.02%	8.95%	2.07%	1.95%	-4.82%
Return on Net Nonoperating Assets (RNNOA)	-608.18%	1,532.19%	246.67%	245.25%	-139.92%	-49.29%	116.24%	127.57%	18.48%	17.26%	-40.35%
Return on Equity (ROE)	-597.18%	1,540.24%	256.66%	256.15%	-140.99%	-47.91%	127.45%	138.42%	21.87%	20.39%	-46.97%
Cash Return on Invested Capital (CROIC)	15.43%	18.09%	17.65%	12.39%	14.61%	14.28%	14.75%	10.79%	5.07%	-1.69%	-5.51%
Operating Return on Assets (OROA)	11.27%	5.08%	8.64%	8.84%	-1.05%	1.80%	7.52%	8.03%	4.33%	3.72%	4.45%
Return on Assets (ROA)	2.94%	-2.28%	1.26%	1.72%	-8.73%	-9.96%	2.55%	2.96%	-1.09%	-0.55%	-0.24%
Return on Common Equity (ROCE)	-1,535.39%	-8,220.83%	386.42%	373.47%	-223.40%	-56.42%	196.25%	221.65%	25.58%	22.66%	-49.48%
Return on Equity Simple (ROE_SIMPLE)	-24.62%	0.00%	156.78%	231.80%	188.79%	0.00%	11.72%	3.56%	-87.78%	0.00%	-90.56%
Net Operating Profit after Tax (NOPAT)	66	53	68	79	-7.52	9.94	82	80	24	25	-49
NOPAT Margin	9.48%	7.26%	9.64%	11.19%	-1.14%	1.61%	13.30%	13.37%	4.33%	4.14%	-8.91%
Net Nonoperating Expense Percent (NNEP)	1.67%	2.94%	2.23%	2.40%	2.86%	3.89%	2.19%	1.89%	1.31%	1.18%	-1.80%
Return On Investment Capital (ROIC_SIMPLE)	2.81%	2.18%	-	-	-	0.37%	-	-	-	0.86%	-
Cost of Revenue to Revenue	63.20%	64.02%	61.63%	64.38%	63.89%	69.23%	62.50%	63.27%	68.04%	64.68%	64.40%
SG&A Expenses to Revenue	17.01%	17.62%	16.90%	16.60%	17.08%	17.67%	18.23%	17.62%	18.31%	16.75%	18.34%
R&D to Revenue	6.01%	8.23%	8.70%	5.14%	5.96%	8.09%	6.67%	6.31%	6.94%	7.59%	9.21%
Operating Expenses to Revenue	22.37%	25.61%	25.73%	22.01%	37.74%	28.47%	25.30%	23.36%	25.78%	29.41%	27.47%
Earnings before Interest and Taxes (EBIT)	94	46	81	86	-9.82	17	74	81	40	40	45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	161	139	141	143	46	78	133	140	100	103	108
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	94.07	3.91	2.98	1.43	2.02	2.06
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.92	0.88	0.96	0.75	0.75	0.78	0.54	0.41	0.19	0.27	0.29
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	125.22	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.80%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.16	2.08	2.10	1.79	1.76	1.69	1.35	1.23	1.05	1.10	1.11
Enterprise Value to Revenue (EV/Rev)	1.80	1.77	1.90	1.76	1.78	1.88	1.56	1.47	1.29	1.46	1.51
Enterprise Value to EBITDA (EV/EBITDA)	8.80	10.54	12.58	11.54	11.28	9.96	7.80	7.54	16.65	20.23	23.50
Enterprise Value to EBIT (EV/EBIT)	16.52	24.28	29.26	27.43	27.57	21.32	15.88	16.62	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	25.25	28.32	38.78	37.50	39.95	31.47	15.06	22.76	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	16.57	16.75	16.29	18.15	22.10	13.03	19.92	17.13	34.70	49.50	21.33
Enterprise Value to Free Cash Flow (EV/FCFF)	13.52	10.84	11.17	13.87	11.44	11.31	8.89	11.06	19.89	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-41.69	-57.09	-75.25	-642.51	-155.98	44.03	13.84	14.76	17.21	13.13	12.91
Long-Term Debt to Equity	-36.27	-49.82	-64.42	-535.43	-143.18	40.55	13.28	13.94	16.41	12.70	12.50
Financial Leverage	-65.16	299.68	31.78	28.83	35.60	19.64	12.89	14.25	8.92	8.87	8.37
Leverage Ratio	-89.76	415.96	45.33	40.33	48.65	26.91	18.53	20.72	12.82	13.05	12.76
Compound Leverage Factor	-35.64	-137.50	8.64	9.55	374.20	-132.96	5.76	7.63	-3.03	-2.52	0.62
Debt to Total Capital	102.46%	101.78%	101.35%	100.16%	100.65%	97.78%	93.26%	93.66%	94.51%	92.92%	92.81%
Short-Term Debt to Total Capital	13.32%	12.98%	14.58%	16.69%	8.26%	7.72%	3.75%	5.22%	4.40%	3.05%	2.98%
Long-Term Debt to Total Capital	89.14%	88.81%	86.76%	83.46%	92.38%	90.06%	89.51%	88.44%	90.11%	89.87%	89.83%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.99%	2.59%	2.39%	2.05%	1.83%	1.50%	-4.91%	-4.69%	-4.48%	-3.03%	-2.68%
Common Equity to Total Capital	-5.45%	-4.37%	-3.74%	-2.20%	-2.48%	0.72%	11.65%	11.04%	9.97%	10.11%	9.87%
Debt to EBITDA	4.29	5.42	6.26	6.58	6.56	5.97	5.56	5.98	15.87	17.22	20.33
Net Debt to EBITDA	4.18	5.17	6.07	6.47	6.45	5.75	5.38	5.74	15.01	17.00	19.63
Long-Term Debt to EBITDA	3.73	4.73	5.36	5.48	6.02	5.50	5.33	5.65	15.13	16.65	19.67
Debt to NOPAT	12.29	14.57	19.29	21.38	23.25	18.87	10.74	18.06	-47.61	-41.28	-33.37
Net Debt to NOPAT	11.99	13.89	18.72	21.03	22.83	18.17	10.39	17.33	-45.03	-40.74	-32.22
Long-Term Debt to NOPAT	10.69	12.71	16.51	17.82	21.34	17.38	10.31	17.05	-45.39	-39.92	-32.29
Altman Z-Score	1.30	1.17	1.21	1.05	0.99	1.02	1.01	0.92	0.78	0.78	0.73
Noncontrolling Interest Sharing Ratio	-157.11%	633.73%	-50.56%	-45.80%	-58.45%	-17.75%	-53.99%	-60.13%	-16.98%	-11.13%	-5.35%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.40	1.41	1.38	1.33	1.65	1.63	1.91	1.83	1.86	1.88	1.74
Quick Ratio	0.76	0.78	0.76	0.74	0.86	0.83	1.02	1.01	0.98	1.02	0.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	241	334	393	287	270	265	254	238	230	42	-124
Operating Cash Flow to CapEx	54.48%	525.63%	828.51%	370.49%	-43.84%	1,151.82%	652.35%	-101.90%	1,225.65%	-203.14%	533.71%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.83	0.80	0.75	0.72	0.70	0.66	0.63	0.60	0.60	0.57	0.55
Accounts Receivable Turnover	3.97	4.02	3.70	3.57	4.10	3.53	3.61	3.39	4.19	3.15	3.40
Inventory Turnover	3.06	2.97	2.96	3.00	2.94	2.83	2.75	2.78	2.85	2.80	2.64
Fixed Asset Turnover	6.53	6.40	6.07	5.87	5.53	5.22	5.18	4.90	4.72	4.50	4.60
Accounts Payable Turnover	2.82	2.73	2.78	2.90	3.05	2.91	2.81	2.68	2.86	2.56	2.43
Days Sales Outstanding (DSO)	91.90	90.85	98.67	102.11	88.96	103.46	101.18	107.76	87.17	115.99	107.46
Days Inventory Outstanding (DIO)	119.37	122.85	123.51	121.79	124.28	129.03	132.74	131.48	128.07	130.41	138.35
Days Payable Outstanding (DPO)	129.38	133.75	131.14	126.07	119.54	125.61	129.93	135.95	127.64	142.40	150.45
Cash Conversion Cycle (CCC)	81.89	79.96	91.04	97.82	93.70	106.88	103.99	103.28	87.59	104.00	95.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,351	2,380	2,422	2,563	2,525	2,661	2,747	2,771	2,803	2,916	2,919
Invested Capital Turnover	1.16	1.11	1.04	0.97	0.94	0.86	0.84	0.81	0.78	0.76	0.74
Increase / (Decrease) in Invested Capital	-175	-281	-325	-208	-278	-255	-171	-158	-206	-17	75
Enterprise Value (EV)	5,086	4,943	5,095	4,583	4,451	4,502	3,715	3,402	2,931	3,222	3,234
Market Capitalization	2,598	2,454	2,575	1,960	1,860	1,861	1,293	947	422	604	613
Book Value per Share	($0.42)	($0.35)	($0.30)	($0.19)	($0.21)	$0.06	$1.08	$1.04	$0.97	$0.98	$0.98
Tangible Book Value per Share	($4.58)	($4.64)	($4.76)	($4.78)	($4.96)	($4.79)	($4.08)	($4.24)	($4.48)	($4.60)	($4.81)
Total Capital	2,416	2,498	2,501	2,609	2,574	2,760	2,840	2,882	2,954	2,952	3,014
Total Debt	2,476	2,543	2,534	2,613	2,590	2,699	2,648	2,700	2,792	2,743	2,798
Total Long-Term Debt	2,154	2,219	2,170	2,178	2,378	2,486	2,542	2,549	2,662	2,653	2,708
Net Debt	2,417	2,424	2,460	2,569	2,544	2,600	2,561	2,590	2,641	2,707	2,702
Capital Expenditures (CapEx)	14	22	17	11	10	12	12	11	11	11	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	697	664	709	763	712	645	715	686	583	714	596
Debt-free Net Working Capital (DFNWC)	756	782	783	807	758	744	802	795	734	749	692
Net Working Capital (NWC)	435	458	418	371	546	531	695	644	604	659	602
Net Nonoperating Expense (NNE)	41	74	56	62	74	103	57	50	34	31	-46
Net Nonoperating Obligations (NNO)	2,410	2,424	2,456	2,567	2,542	2,600	2,556	2,588	2,641	2,707	2,702
Total Depreciation and Amortization (D&A)	67	93	60	57	56	62	60	60	60	63	64
Debt-free, Cash-free Net Working Capital to Revenue	24.64%	23.76%	26.44%	29.36%	28.53%	26.96%	29.96%	29.65%	25.64%	32.26%	27.85%
Debt-free Net Working Capital to Revenue	26.73%	28.00%	29.20%	31.05%	30.39%	31.10%	33.61%	34.38%	32.28%	33.86%	32.33%
Net Working Capital to Revenue	15.36%	16.39%	15.60%	14.29%	21.87%	22.20%	29.14%	27.87%	26.57%	29.79%	28.13%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.04	($0.10)	$0.00	$0.02	($0.30)	($0.57)	$0.06	$0.08	($0.05)	($0.03)	($0.02)
Adjusted Weighted Average Basic Shares Outstanding	311.05M	308.98M	309.65M	309.12M	307.28M	176.14M	154.22M	153.74M	152.11M	150.94M	151.39M
Adjusted Diluted Earnings per Share	$0.04	($0.10)	$0.00	$0.02	($0.30)	($0.57)	$0.06	$0.08	($0.05)	($0.03)	($0.02)
Adjusted Weighted Average Diluted Shares Outstanding	323.96M	308.98M	309.65M	318.96M	307.28M	176.14M	159.69M	154.89M	152.11M	150.94M	151.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	313.42M	309.97M	309.84M	309.54M	308.65M	307.01M	306.54M	306.31M	305.45M	303.62M	303.59M
Normalized Net Operating Profit after Tax (NOPAT)	66	55	67	79	60	2.42	54	53	26	42	31
Normalized NOPAT Margin	9.53%	7.48%	9.53%	11.30%	9.05%	0.39%	8.71%	8.86%	4.64%	6.93%	5.62%
Pre Tax Income Margin	5.39%	-2.10%	2.20%	2.91%	-11.46%	-13.53%	3.70%	4.95%	-1.69%	-1.26%	0.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	59.46%	-26.81%	-11.91%	-33.19%	-44.27%	-145.48%	186.51%	380.88%	-12.62%	-6.89%	-12.47%
Augmented Payout Ratio	59.46%	-26.81%	-11.91%	-33.19%	-44.27%	-145.48%	186.51%	380.88%	-12.62%	-7.57%	-13.11%

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

When does Amneal Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Amneal Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amneal Pharmaceuticals' net income changed over the last 8 years?

Amneal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$73.88 million in 2024, falling from $209.43 million in 2016. The previous period was -$48.72 million in 2023. View Amneal Pharmaceuticals' forecast to see where analysts expect Amneal Pharmaceuticals to go next.

What is Amneal Pharmaceuticals's operating income?

Amneal Pharmaceuticals's total operating income in 2024 was $249.33 million, based on the following breakdown:

Total Gross Profit: $1.02 billion
Total Operating Expenses: $771.11 million

How has Amneal Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Amneal Pharmaceuticals' total revenue changed from $1.02 billion in 2016 to $2.79 billion in 2024, a change of 174.4%.

How much debt does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals' total liabilities were at $3.55 billion at the end of 2024, a 3.9% increase from 2023, and a 106.5% increase since 2017.

How much cash does Amneal Pharmaceuticals have?

In the past 7 years, Amneal Pharmaceuticals' cash and equivalents has ranged from $25.98 million in 2022 to $341.38 million in 2020, and is currently $110.55 million as of their latest financial filing in 2024.

How has Amneal Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Amneal Pharmaceuticals' book value per share changed from 0.00 in 2016 to -0.35 in 2024, a change of -35.3%.

Related Companies

This page (NASDAQ:AMRX) was last updated on 5/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Financials

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Financials

Annual Income Statements for Amneal Pharmaceuticals

Quarterly Income Statements for Amneal Pharmaceuticals

Annual Cash Flow Statements for Amneal Pharmaceuticals

Quarterly Cash Flow Statements for Amneal Pharmaceuticals

Annual Balance Sheets for Amneal Pharmaceuticals

Quarterly Balance Sheets for Amneal Pharmaceuticals

Annual Metrics And Ratios for Amneal Pharmaceuticals

Quarterly Metrics And Ratios for Amneal Pharmaceuticals

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools